Mortality of Patients Infected by COVID-19 with and without Deep-Vein Thrombosis
Jose Maria Pereira de Godoy,
Gleison Juliano da Silva Russeff,
Carolina Hungaro Costa,
Debora Yuri Sato,
Desirée Franccini Del Frari Silva,
Maria de Fatima Guerreiro Godoy,
Henrique Jose Pereira de Godoy,
Paulo César Espada
Affiliations
Jose Maria Pereira de Godoy
Cardiovascular Surgery Department, Sao Jose do Rio Preto School of Medicine (FAMERP), Undergraduate Medicine Course and <i>Stricto Sensu</i> Postgraduate Course (FAMERP) and CNPq (National Council for Research and Development), São Jose do Rio Preto 15025120, Brazil
Gleison Juliano da Silva Russeff
Vascular Surgery Echography Service, Hospital Affiliated with Sao Jose do Rio Preto School of Medicine (FAMERP), São Jose do Rio Preto 15025120, Brazil
Carolina Hungaro Costa
Vascular Surgery Echography Service, Hospital Affiliated with Sao Jose do Rio Preto School of Medicine (FAMERP), São Jose do Rio Preto 15025120, Brazil
Debora Yuri Sato
Vascular Surgery Echography Service, Hospital Affiliated with Sao Jose do Rio Preto School of Medicine (FAMERP), São Jose do Rio Preto 15025120, Brazil
Desirée Franccini Del Frari Silva
Vascular Surgery Echography Service, Hospital Affiliated with Sao Jose do Rio Preto School of Medicine (FAMERP), São Jose do Rio Preto 15025120, Brazil
Maria de Fatima Guerreiro Godoy
<i>Stricto Sensu</i> Postgraduate Program, Sao Jose do Rio Preto School of Medicine (FAMERP), Research Group at Godoy Clinic, Sao Jose do Rio Preto 15025120, Brazil
Henrique Jose Pereira de Godoy
Department of General Surgery, Sao Jose do Rio Preto School of Medicine (FAMERP), São Jose do Rio Preto 15025120, Brazil
Paulo César Espada
Trauma Surgery, Sao Jose do Rio Preto School of Medicine (FAMERP), São Jose do Rio Preto 15025120, Brazil
Background: Current evidence points to a state of hypercoagulability (consequence of hyperinflammation) as an important pathogenic mechanism that contributes to the increase in mortality in cases of COVID-19. The aim of the present study was to investigate the influence of deep-vein thrombosis on mortality patient’s infected with SARS-CoV-2. Method: A clinical trial was conducted involving 200 consecutive patients with COVID-19—100 patients who were positive for deep-vein thrombosis (venous Doppler ultrasound) and 100 who were negative for deep-vein thrombosis at a public hospital. Results: The mortality rate was 67% in the group positive for DVT and 31% in the group negative for DVT. Conclusion: Deep-vein thrombosis is associated with an increase in mortality in patients with COVID-19 and failures can occur with conventional prophylaxis for deep-vein thrombosis.
